Among these, TNBC characterized by the absence of the ER, PR, and HER2, accounts for approximately 10–20% of all breast cancer cases and is the most malignant subtype of breast cancer because of high heterogeneity, aggressiveness, and lack of treatment options [3,4]. This evidence concerns the gene PGR and breast carcinoma.